Supernus Pharma (SUPN) Misses Q4 EPS by 48c, provides guidance

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.07), $0.48 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $211.6 million versus the consensus estimate of $195.48 million.

GUIDANCE:

Supernus Pharma sees FY2026 revenue of $840-870 million, versus the consensus of $861.2 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• ArcelorMittal (MT:NA) (MT) PT Raised to EUR65 at Jefferies
• Morgan Stanley Resumes Tapestry Inc. (TPR) at Overweight
• Morgan Stanley Resumes Victoria Secret (VSXY) at Overweight